Related by context. Frequent words. (Click for all words.) 71 Inc Therapeutic Competitors 71 Nasdaq REGN 71 Inc. Nasdaq IMGN 70 Nasdaq VRTX 70 Nasdaq DNDN 69 NASDAQ ARIA 69 IDIX 69 NASDAQ IMCL 68 Nasdaq AMLN 68 Nasdaq BIIB 68 NASDAQ SHPGY 68 Presents Positive 68 Inc. NASDAQ TRGT 67 Nasdaq ITMN 67 R sorafenib tablets 66 AUXL 66 Metabasis Therapeutics Inc. 66 Tranzyme Pharma 66 Cyclacel Pharmaceuticals Inc. 66 EPIX Pharmaceuticals Inc. 66 Calls Purchased 66 ARIAD Pharmaceuticals Inc. 66 OPTR 66 Completes Enrollment 66 Idera Pharmaceuticals 66 ONXX 65 Exploit collaboration 65 ENZN 65 Nasdaq BDSI 65 Nektar Therapeutics NKTR 65 Inc. Nasdaq SGEN 65 QGEN 65 Nasdaq CELG 65 NYSE MYL 65 Nasdaq AMGN 65 Nasdaq ALTH 65 Announces Presentation 64 Inc. Nasdaq HGSI 64 NASDAQ CELG 64 NovaBay Pharmaceuticals 64 DVAX 64 Inc. Nasdaq ARNA 64 Celsion Corporation 64 ImmunoCellular Therapeutics 64 Nasdaq ISIS 64 Options Trader Alert 64 Inc. NASDAQ ALKS 64 Report companiesandmarkets.com adds 64 Adolor Corporation 64 LXRX 64 Neurogen Corporation 64 SGMO 64 Inc. NASDAQ MRNA 64 RegeneRx Biopharmaceuticals Inc. 64 REGN 64 Inc. NYSE FRX 64 IMGN 64 Inc. NASDAQ CLDA 64 Stock Upgraded 64 IDEV 64 Inc. NASDAQ RRGB 64 Sunesis Pharmaceuticals Inc. 64 Company NASDAQ MDCO 64 VIA Pharmaceuticals 64 ZIOPHARM Oncology Inc. 63 Inc. Nasdaq EXEL 63 Novelos Therapeutics Inc. 63 BPAX 63 ALNY 63 Pharmion Corporation 63 AEterna Zentaris Inc. 63 Biogen Idec NASDAQ BIIB 63 NASDAQ CBST 63 Company Nasdaq PRGO 63 Regado Biosciences 63 QLTI 63 INCY 63 Achillion Pharmaceuticals Inc. 63 AFFY 63 Genaera Corporation 63 Rexahn Pharmaceuticals Inc. 63 Nasdaq ALKS 63 NASDAQ CRXL 63 Inc. NASDAQ BIIB 63 Callisto Pharmaceuticals Inc. 63 Q2 Loss Narrows 63 NovaBay Pharmaceuticals Inc. 63 Anadys Pharmaceuticals Inc. 63 ImmunoGen Inc. 63 CRXX 62 Immunomedics Inc. 62 Interesting Options Volume 62 Progenics Pharmaceuticals 62 Sciele Pharma Inc. 62 Bearish Pressure Building 62 Ironwood Pharmaceuticals Inc. 62 Halozyme Therapeutics 62 Cardium Therapeutics Inc. 62 Options Brief 62 Guides FY# Quick Facts 62 CRME